EZH2 inhibits NK cell–mediated antitumor immunity by suppressing CXCL10 expression in an HDAC10-dependent manner is a research paper published in Proceedings of the National Academy of Sciences (2021). On theSindex it has a DataRank of 0. It has been cited 79 times.
Scored on demand from live citation data
Linked data & code
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
HHS | National Institutes of Health
Grant: R01CA218008
HHS | National Institutes of Health
Grant: R01CA257046
U.S. Department of Defense
Grant: W81XWH1910480
U.S. Department of Defense
Grant: W81XWH-18-1-0069
National Institutes of Health
Grant: 5R01CA257046-05
Deciphering and targeting a non-genetic driver pathway in hepatocellular carcinoma
National Institutes of Health
Grant: 1R01CA218008-01A1
A Novel Druggable Epigenetic Vulnerability Pathway in HCC
FWCI
3.89
Citation Percentile
1.0%
Citation Trend
Fields of Study
MeSH Terms
Keywords
Sustainable Development Goals
Additional file 2 of Cantharidin suppresses hepatocellular carcinoma development by regulating EZH2/H3K27me3-dependent cell cycle progression and antitumour immune response
Additional file 2 of Cantharidin suppresses hepatocellular carcinoma development by regulating EZH2/H3K27me3-dependent cell cycle progression and antitumour immune response
Additional file 1 of Cantharidin suppresses hepatocellular carcinoma development by regulating EZH2/H3K27me3-dependent cell cycle progression and antitumour immune response
Additional file 1 of Cantharidin suppresses hepatocellular carcinoma development by regulating EZH2/H3K27me3-dependent cell cycle progression and antitumour immune response